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Abstract
Objective—To identify risk factors for loss to follow up (LTFU) in an HIV-infected pediatric 
population in Dar es Salaam, Tanzania between 2004 and 2011.
Design—Longitudinal analysis of 6236 HIV-infected children.
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Methods—We conducted a prospective cohort study of 6236 pediatric patients enrolled in care 
and treatment in Dar es Salaam from October 2004 to September 2011. LTFU was defined as 
missing a clinic visit for >90 days for patients on ART and for >180 days for patients in care and 
monitoring. The relationship of baseline and time-varying characteristics to risk of LTFU was 
examined using a Cox proportional hazards model.
Results—2130 children (34%) were LTFU over a median follow up of 16.7 months (IQR, 3.4–
36.9). Factors independently associated with a higher risk of LTFU were age 2 years (RR=1.59, 
95% CI 1.40–1.80), diarrhea at enrollment (RR=1.20, 95% CI 1.03–1.41), a low mid-upper arm 
circumference for age (RR=1.20, CI 1.05–1.37), eating protein 3 times a week (RR=1.39, 95% CI 
1.05–1.90), taking cotrimoxazole (RR=1.39, 95% CI 1.06–1.81), initiating onto antiretrovirals 
(RR=1.37, 95% CI 1.17–1.61), receiving treatment at a hospital instead of a local facility 
(RR=1.39, 95% CI 1.06–1.41), and starting treatment in 2006 or later (RR=1.10, 95% CI 1.04–
1.16).
Conclusions—Health workers should be aware of pediatric patients who are at greatest risk of 
LTFU, such as younger and undernourished patients, so that they can proactively counsel families 
about the importance of visit adherence. Findings support decentralization of HIV care to local 
facilities as opposed to hospitals.
Keywords
Africa; Tanzania; antiretroviral therapy; pediatrics; HIV/AIDS; adherence
Introduction
Patient loss to follow up (LTFU) is a crucial obstacle for successful HIV care and treatment. 
While evidence indicates that children should be initiated onto antiretrovirals (ARVs) as 
soon as possible,1 only 26% of children worldwide requiring treatment are receiving it and 
many of them are lost at various stages of the HIV treatment continuum.2 As more countries 
move to initiate children immediately upon HIV diagnosis, retention after initiation is of 
paramount importance, particularly so as to reduce resistance to ARVs3. Resistance to 
ARVs develops when patients go on and then off their treatment long enough for the HIV 
genome to mutate a defense against the drug’s effects.4 Patients can then pass on the drug-
resistant strain and those infected die for lack of effective ARVs5. Hence, retaining children 
on treatment becomes important because they could live long lives with ample opportunity 
to infect others with resistant strains.6 Currently, improving retention to reduce LTFU of 
pediatric patients continues to be a challenge in Sub-Saharan Africa (SSA), including in 
Tanzania.2
While children in HIV treatment programs have higher retention rates than adults, a rise in 
LTFU has been observed as pediatric HIV programs scale up.7 In Tanzania, research shows 
that healthier HIV-positive adults, men in particular, are more at risk of LTFU and death, 8,9 
whereas research from other SSA countries indicates that the youngest and sicker children, 
regardless of gender, are more at risk for LTFU.10–18 SSA studies have also indicated that 
the child’s caregiver and the nearness of their clinic significantly impact the child’s 
adherence to treatment.19,20 It is important to determine if these findings apply to Tanzanian 
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children since research has emphasized the need to tailor retention strategies to those 
patients most at risk of LTFU. 2,7,21 This study strives to fill the research gap on pediatric 
LTFU in Tanzania. In addition to analyzing clinical variables, this study also includes 
socioeconomic and demographic variables that appear to be of increasing importance but 
have rarely been included in previous studies of risk factors for LTFU among children. 
Finally, this study analyzes if hospital-based or decentralized care at health centers and 
dispensaries is associated with increased LTFU.
Methods
Study Population
In 2004 in Dar es Salaam, Tanzania, a joint partnership was formed between Muhimbili 
University of Health and Allies Sciences, the Dar es Salaam City council, and the Harvard 
School of Public Health (HSPH) in order to support HIV services in the city. With financial 
support from the President’s Emergency Plan of AIDS Relief (PEPFAR), MDH continues to 
provide HIV care and treatment support in Dar es Salaam. Between November 2004 and 
September 2011, MDH enrolled 6579 HIV-infected children (<15 years old) into their 
program in Dar es Salaam. Clinical and demographic variables were collected on all these 
patients. Within the 6579 children, 290 of them and their mothers participated in a 
randomized controlled trial of multivitamin supplementation in Dar es Salaam that occurred 
between 2004 and 2008.22 It collected more detailed socioeconomic status (SES) and 
familial characteristics than were collected through the routine PEPFAR program, so in this 
subset we were able to look at the effects of SES and familial characteristics in greater 
depth. A sensitivity analysis was undertaken to ensure that this subset had predictors for 
LTFU similar to those of the full cohort of children. Ethical clearance for this research was 
granted by HSPH in Boston and the National Institute of Medical Research (NIMR) in Dar 
es Salaam.
Study Variables
LTFU was defined separately for patients initiated on antiretroviral therapy (ART) and for 
patients not yet initiated on ART, also known as in care and monitoring, because ART 
patients are required to visit the clinic more often to receive their ARVs. Patients on ART 
were defined as LTFU if their last date of contact with the clinic was >90 days before the 
date of the administrative end of the study on 30 September 2011 and they were not known 
to have died or been transferred to another clinic. Patients on care and monitoring were 
defined as LTFU if their last date of contact with the clinic was >180 days before the date of 
the administrative end of the study and they were not known to have died or been transferred 
to another clinic. The definition for LTFU among ART patients is similar to the 2011 WHO 
working group definition.23
Participant specific factors, including demographic, socioeconomic, and nutritional 
characteristics as well as immunological status, were considered. Standardized weight-for-
age (WAZ), height/length-for-age (HAZ), weight-for-height/length (WHZ) Z-scores (for 
children ≤2 years) and body mass index (BMIZ) Z-scores (for children >2 years) were 
calculated using the WHO Child Growth Standard reference data.24 A child was considered 
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to be underweight, stunted, or wasted when WAZ, HAZ, or WHZ/BMIZ Z-score 
respectively was below −2 of the reference population. Z-scores that are considered 
unphysiologic (>+6 or <−6) were coded as missing.24 Low mid-upper arm circumference 
(MUAC) was defined as <11.5cm for children <5 years, <12.9 for children age 5–9 years, 
and <16.0cm for children age ≥10.25 Elevated alanine aminotransferase (ALT) was defined 
as >40 (U/l) for children aged ≤5 years26 and >30 (U/l) for children >5.27 Anemia was 
measured by age-specific hemoglobin level: for children <2 years, hemoglobin <9.5 g/dl; 
>2–<7 years, hemoglobin <11.0 g/dl; 7–<11 years, hemoglobin <11.5 g/dl; ≥11 years, 
hemoglobin <12.0 g/dl.28 Because the ART program did not begin until September 2004, 
years 2004 and 2005 were combined in the analysis. Years 2006 and 2007 were combined 
because of pediatric ART guideline changes. Before 2007, for children aged <18 months, 
eligibility was based on CD4% <20 or WHO stage 3; for children aged ≥ 18 months, 
eligibility was based on WHO stage 3 or CD4% <15%.29 After 2007, practices changed and 
updated guidelines reflect that all children <12 months were initiated regardless of CD4% or 
WHO stage; for children aged ≥18–59 months, eligibility was based on WHO stage 3 or 
CD4% <20%; and for children ≥60 months, eligibility was based on WHO stage 3 or CD4% 
<15%.30 Cotrimoxazole was given to all exposed babies that continued to breastfeed and to 
all symptomatic patients with CD4 counts <350 cells per μL or a CD4% <25%.31 The 
caretaker variable was defined as either a ‘parent’ or ‘other’, meaning friend, sibling, or 
extended family member. The household belongings variable was measured as the number 
of following belongings the patient’s family had in the house and is based on items the 
Tanzanian government uses to assess SES: a sofa, TV, fan, radio, and refrigerator.32 Finally 
the facility-type variable was defined as either a dispensary, healthcare center, or a hospital. 
Dispensaries provide basic reproductive, child, and outpatient care services, including ART, 
to between 6000 and 10000 people.33 Supervising the dispensaries are healthcare centers 
that serve between 10000 and 50000 people. They provide preventative outpatient care as 
well as reproductive and minor surgical services.33 Finally, hospitals serve between 50000 
and 1.4 million people and offer outpatient and inpatient services not available at 
dispensaries or health centers, including laboratory, x-ray, surgical, and emergency obstetric 
services.33
Statistical Analysis
Kaplan-Meier (KM) curves were used to estimate cumulative incidence of LTFU over the 
study period. The incidence rate for LTFU was calculated from the date of enrollment into 
the program and 95% confidence intervals (CI) were calculated using the Poisson 
distribution. The associations between baseline characteristics and LTFU were examined 
using a Cox proportional hazards model while the associations between time-varying 
characteristics and LTFU were examined in a separate Cox proportional hazards model. 
Children were censored when they died, at the end of study in December 2011 if they were 
event free, or at their last visit date if they were LTFU. Four anthropometric indicators, 
weight-for-length/BMI Z-score, height-for-age Z-score, weight-for-age Z-score, and 
MUAC, were examined separately in multivariate regression models because of their high 
correlations. Relative risks (RR), in particular, hazard ratios, 95% CIs, and corresponding P 
values were obtained from the models adjusting for multiple covariates. Variables were 
included in the multivariate models if the estimated RR for their association with LTFU was 
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statistically significant at P 0.20 in the univariate analyses34 or if we reasoned, such as based 
on literature, that they could be mechanistically related to LTFU.11,13,35 When potential risk 
factor data were unavailable, the missing indicator method was used.36 The criterion for 
significance for all the analyses was a P value 0.05. All P values were two-sided. Statistical 
analyses were performed with the statistical software package SAS (version 9.2, SAS 
Institute Inc., Cary, NC).
Results
From November 2004 to September 2011, 6579 children attended a treatment clinic at least 
once. Of these, 343 (5.21%) were excluded from the analysis because they never returned to 
the clinic (or any other MDH clinic) after their first visit. These 343 children would not have 
been considered part of MDH’s program since they did not receive their CD4 results and 
could not be placed either on ART or in the care and monitoring program. Of the 6236 
children eligible for this study, 2130 (34%) were LTFU over 11710 years of follow-up, 
giving an incidence rate of 18.2 (95% CI 17.4–19.0) per 100 child-years of follow up. The 
characteristics of the participants at the time of enrollment into MDH are summarized in 
Table 1. The median age at enrollment was 5 years old and approximately one-half of the 
children were female. Fifty percent of the participants were WHO stage 3 or 4 and 67% had 
a CD4 count <350 or a CD4 percentage <20%. Fifty-two percent of children were on 
cotrimoxazole and 15% had a history of TB infection. Seventeen percent of children had a 
low MUAC for their age and over a quarter were undernourished as defined by underweight 
or stunting. Ten percent of children presented with diarrhea and 13% with opportunistic 
infections. Seventy-three percent of the children’s records indicated that their parent was 
their primary caretaker. Although 54% of the children’s families reported spending over 
500Tsh (0.32 USD) on food per person per day, 71% reported that the child ate protein >3 
times a week.
A summary of participant characteristics associated with LTFU, both baseline and time-
varying characteristics, is provided in Table 2. After multivariate adjustment, factors 
associated with an increase in the risk of LTFU included age ≤2 years (RR=1.59, 95% CI 
1.40–1.80), diarrhea at enrollment (RR=1.20, 95% CI 1.03–1.41), a low MUAC for age 
(RR=1.20, 95% CI 1.05–1.37), taking cotrimoxazole (RR=1.39, 95% CI 1.06–1.81), 
initiating onto ARVs (RR=1.37, 95% CI 1.17–1.61), receiving treatment at a hospital as 
opposed to a healthcare center or dispensary (RR=1.39, 95% CI 1.06–1.41), and starting 
treatment in 2006 or later, where the RRs for LTFU increased log-linearly for each 
successive year since the program began (p<0.001). The KM curve of LTFU of children 
who were and were not initiated onto ART at enrollment can be seen in Figure 1 and the 
KM curve of LTFU of children with and without diarrhea at enrollment can be seen in 
Figure 2. Although not significant, results also indicated that having a caregiver with 
positive or unknown HIV status also increased risk of LTFU among children. The 
association between the SES and familial characteristics are provided in Table 3. After 
multivariate adjustment, the factor associated with LTFU was eating protein (e.g. fish or 
meat) at a meal ≤3 times a week (RR=1.39, 95% CI 1.05–1.90). Protein is an expensive food 
source in Tanzania;37 therefore, this variable can serve as a proxy for SES and indicates that 
children from lower SES homes are more likely to become LTFU. A sensitivity analysis 
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indicated that the 290 children who had participated in a trial embedded within the overall 
cohort had similar patient characteristics and the same predictors of LTFU as the larger 
MDH cohort and that the results of our analysis do not change when this subset is deleted.
Discussion
We identified predictors of LTFU in a cohort of 6236 HIV-positive Tanzanian children who 
had an incidence of LTFU of 18.2 (95% CI 17.4–19.0) per 100 child-years of follow up. 
This is similar to studies of other SSA cohorts which have reported incidence rates of 13.6 
(11.6–16.1), 18.4 (17.8–18.9), and 26.2 (25.9–26.4) per 100-child years, but smaller 
compared to a Gambia study’s LTFU incidence rate of 115.7 (98.8–137.0) per 100 child-
years of follow up.13 Our study population is one of the largest reported cohorts of HIV-
positive children in East Africa for whom clinical, demographic, and SES longitudinal data 
are prospectively available. An important finding of this study not previously reported was 
the increased risk of LTFU among children presenting with diarrhea at enrolment. Other 
important findings were the increased risk of LTFU among children receiving treatment at 
hospitals as opposed to local facilities and among children ≤2 years.
Although not previously identified in other studies, often because data were unavailable, our 
study demonstrated that diarrhea at enrollment was associated with an increased risk of 
LTFU by 20% compared to children without diarrhea. Diarrhea is both a symptom of HIV 
disease as well as many other childhood infections that contribute to high morbidity and 
mortality among SSA children.38,39 A limitation of our diarrhea variable was that it did not 
indicate if the episode was acute or chronic. In developing countries, diarrhea, specifically 
chronic diarrhea, is most common among children ≤2 years.40 In our study, 35% of the ≤2 
year olds had diarrhea, a higher percentage than in any other age group. In other SSA 
settings, cohorts of HIV-infected children ≤2 years report similar proportions of diarrhea 
incidence while cohorts of non-HIV infected children report lower rates of diarrhea.41,42 
Diarrheal diseases account for >25% of deaths for children <5 in SSA and it could be that 
the children who had diarrhea at enrollment and who were LTFU in fact died, but we were 
unable to confirm this.43 It is also important to note that several studies have found that 
patients loss to follow-up in ART programmes in SSA are over 3 times as likely to die than 
patients who remain in care;44,45 therefore a useful follow up to our study would be to 
ascertain the mortality rate among patients who become LTFU to be able to better design 
strategies to prevent both LTFU and otherwise unrecognized mortality.
Children treated at hospitals were at greater risk for LTFU than those treated at local 
dispensaries even after multivariate adjustment which indicates that the effect is not 
confounded by sicker children receiving treatment at hospitals. A 2010 study in South 
Africa comparing LTFU from hospitals versus primary healthcare facilities (PHCs) found 
that patient outcomes were superior at PHCs, despite PHC-patients having more advanced 
clinical stage disease when starting ART.46 This may be because patients do not have to 
travel as far or to spend as much money to reach PHCs compared to hospitals.47 Our 
findings support research from many SSA countries that has found the expansion of 
pediatric HIV services from tertiary to PHCs has resulted in increased numbers of children 
on ART and in lower rates of LTFU and mortality.48–50 Tanzanian policy makers should 
MCCORMICK et al. Page 6













continue decentralizing ART care to local facilities to allow children and their parents’ easy 
access to ART. Young children especially cannot receive treatment if their parents cannot 
take them to a point of care.
In our study, children ≤2 years were 60% more likely to become LTFU than older children. 
A recent meta-analysis on the magnitude of LTFU using studies from South Africa, Uganda, 
Kenya, and Nigeria demonstrated that children ≤2 years were the most likely age group to 
become LTFU. The two South Africa programs reported they lost 85.1% and 50.2% of 
infants 12 months after birth respectively while the Ugandan, Kenyan and Nigerian 
programs reported they lost 53.4%, 66.1%, and 20.8% of infants 18 months after birth 
respectively.7 In addition, a study of 258 Malawian children between 2004 to 2006 found 
that factors significantly associated with LTFU were age <18 months and WHO stage 4,11 
while a study of 441 Gambian children between 2004 to 2010 also found that age <2 years 
and WHO stage 3 and 4 were significantly associated with LTFU.13 In our cohort, we 
suspect but cannot confirm that the significant number of young children LTFU reflects the 
high mortality rate among exposed children in this age group. Clearly, young patients need 
to be targeted for treatment and prevention of LTFU in the treatment cascade.
Low MUAC for age at enrollment was associated with increased risk of LTFU in our 
population, which is consistent with findings that children with poor nutritional status are at 
increased risk of LTFU in multivariate analyses.21,38,51 In addition, we found that children 
who ate protein ≤3 times a week were more likely to become LTFU than children who ate 
protein >3 times a week. This finding could be interpreted as a sign of poor nutrition as well 
as a proxy for low SES because protein-rich foods, like meat, are expensive in Tanzania and 
are primarily consumed by those with high SES.37,52,53 In addition, meat consumption is 
unlikely to be confounded by religious identification because pork is rarely consumed in 
Tanzania generally.54,55 In support of this hypothesis, children receiving care in Kinondoni 
district were 22% more likely to become LTFU than their peers in Ilala district, who tend to 
have higher SES.56
The results from several studies are consistent with our findings that pediatric LTFU rates 
are increasing with increasing calendar time. The West African leDEA group reported that 
among 2170 pediatric patients, both mortality and LTFU were associated with advanced 
clinical stage, CD4 percentage <15% at ART initiation, and being initiated after 2005.10 A 
2013 paper from South Africa analyzing 4266 children from 2004 to 2011 also found that 
risk factors associated with LTFU after 2 years on treatment were age <1 year, initiating 
ART after 2005, having their mother as their primary caregiver, being underweight (WAZ≤
−2), and low CD4%.18 Increased risk of LTFU in more recent years is likely due to the 
increased patient demand for ART services from a limited number of facilities which 
occurred throughout SSA after that time, with facilities likely being unprepared to handle 
the large influx of patients.2
Published data on the relationship between the caretaker identity e.g. parent, and ART 
adherence in children has been conflicting;57 however, recent studies from Zambia and 
South African have demonstrated that drug adherence is lower among children whose 
mothers are their primary caretaker, most likely because these women are also HIV positive 
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and are therefore sicker and more at risk of dying than their HIV-negative counterparts.18,58 
An HIV positive caretaker could also be afraid of disclosing their child’s or their status for 
fear of discrimination.20 In our study, univariate analyses demonstrated that the caretaker’s 
identity, parent or other, is not associated with LTFU among children, but children whose 
caretaker had positive or unknown HIV status were more likely to be LTFU, although this 
findings was not significant in the multivariate analysis, possibly due to a lack of power. 
Adherence counseling tailored to the caretaker may be an underappreciated factor affecting 
treatment outcomes among HIV-infected children living in Tanzania and similar settings.20
Although it appears counterintuitive, our finding that children initiated on ART at 
enrollment are 37% more likely to become LTFU compared to children in care and 
monitoring is consistent with a 2010 paper evaluating retention of 13510 HIV-infected and 
exposed children in Western Kenya from 2002 to 2009.35 It should be noted that the more 
stringent definition of LTFU is used for those on ART as opposed to those on care and 
monitoring. Thus, the finding could be, at least in part, a consequence of the differing 
definition of LTFU between the two groups. It may also appear counterintuitive that 
cotrimoxazole is a significant predictor of LTFU over time but not at baseline. Currently 
cotrimoxazole use may be a marker for worsened clinical status; however, although 
attenuated, the association remained significant even after extensive multivariate adjustment 
for all measured indicators of clinical status.
The strengths of this study included the large sample size, the prospective nature of the 
design, and the long follow up (median 16.7 months, IQR 3.4–36.9). Furthermore, since the 
study was population-based, the findings may be generalizable among HIV-infected children 
initiating ART in Tanzania as well as in other SSA countries. The limitations to this study 
are that detailed SES and familial data were available for a relatively small subset of 
patients. In addition, only 52.9% of the 6236 children had CD4 count data, but this is largely 
due to Tanzania restricting CD4 count tests to children WHO stage 3 or 4 during the study 
period because of limited resources.
We found that diarrhea at enrolment, receiving ART at hospitals, age ≤2, and poor 
underlying nutritional status are important predictors for LTFU in HIV-infected children. It 
is important from clinical and programmatic perspectives to ensure that treatment programs 
are aware of these vulnerable groups among children and that there is a mechanism to trace 
them as soon as possible after a missed clinic visit. In addition, SSA governments should 
continue to decentralize HIV care and treatment services so that they are easily accessible to 
patients.
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KM plot of LTFU stratified by Initiated onto ART at Enrolment
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KM plot of LTFU stratified by Diarrhea at Enrolment
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1Low MUAC is defined as <11.5cm for children <5 years, below 12.9 for children 5–9 years, and <16.0cm for children aged 10+ 
years.
2Underweight is defined as WAZ<-2SD
3Wasting is defined as WHZ<-2SD if ≤2 years; BMIZ<-2 SD if >2 years
4Stunting is defined as HAZ<-2SD



































































































































































































































































































































































5CD4 count, cells/mm3 OR CD4% if child <12
6 Anemia was defined as hemoglobin <9.5 g/dl for children <2; hemoglobin < 11.0 g/dl for children 2–<7 years; hemoglobin <11.5 g/dl for children 7–<11; and hemoglobin less than 12.0 g/dl for children 11+
7>40 for children aged 5 years or under and >30 for age older than 5 years























































































































































































































































































































































































































































































8Data is from RCT reported in Duggan C, Manji KP, Kupka R, et al. Multiple micronutrient supplementation in Tanzanian infants born to HIV-infected mothers: a randomized, double-blind, placebo-controlled clinical trial. The American journal of clinical nutrition. Dec 2012;96(6):1437–1446.
9Only known if mother is married
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Table 2
Baseline and Time-varying Demographic and Clinical Characteristics in relation to LTFU: 2130 events, 11710 
child-years of follow up
Characteristic Univariate RR 95% CI P for trend Multivariate RR 95% CI P for trend
Demographic Characteristics
Sex
 Male 0.99 (0.91–1.07) 0.4525
 Female Reference
Age group, years10
 ≤2 1.62(1.43–1.83) <0.0001 1.59(1.40–1.80) <0.0001
 >2–5 Reference Reference
 >5–10 0.75(.66–.86) 0.74(.64–.84)
 >10 0.68(0.58–0.79) 0.66(0.56–0.77)
District of Residence
 Ilala Reference 0.03 Reference 0.03
 Kinondoni 1.20 (1.09 –1.33) 1.22 (1.10 –1.35)
 Temeke 1.13 (1.02 –1.26) 1.11 (0.99 –1.24)
Designated Caretaker
 Parent Reference 0.81
 Other 0.96(0.71–1.29)
Parent HIV Status
 Negative Reference 0.073 Reference 0.28
 Positive 1.54(0.21–10.87) 1.46(0.20–10.60)
 Unknown 2.33(0.32–16.35) 2.09(0.29–15.04)
Designated
Caretaker’s HIV Status Reference 0.031 Reference 0.35
 Negative 1.32(0.32–5.37) 1.06(0.26–4.33)




 Dec, Jan, Feb Reference .28
 March, Apr, May 0.97(0.93–1.02)
 June, July, Aug, 0.99(0.90–1.16)
 Sept, Oct, Nov 1.05(0.95–1.28)
Year of Initiation
 2004–2005 Reference <0.0001 Reference <0.0001
 2006–2007 1.28(1.13–1.46) 1.28(1.07–1.54)
 2008 1.33(1.15–1.54) 1.66(1.36–2.02)
 2009 1.68(1.45–1.96) 2.34(1.90–2.89)
10Only results from time-varying model are shown, but both baseline and time-varying analyses were done.
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Characteristic Univariate RR 95% CI P for trend Multivariate RR 95% CI P for trend
 2010 1.81(1.53–2.14) 2.55(2.04–3.19)
 2011 1.81(1.42–2.30) 2.36(1.77–3.15)
Facility level
 Hospital Reference 0.05 Reference <0.0001
 Center 0.69(0.63–0.76) 1.01(0.84–1.21)
 Dispensary 0.42(0.31–0.56) 0.48(0.36–0.65)
Low mid upper arm circumference1
 No Reference 0.0012 Reference 0.0070
 Yes 1.34(1.13–1.60) 1.20(1.05–1.37)
WAZ Score
 WAZ > −1 Reference 0.003 Reference 0.33
 −2< WAZ ≤ −1 0.94(0.81–1.10) 1.00(0.86–1.18)
 −3 < WAZ ≤ −2 0.90(0.76–1.07) 1.04(0.87–1.24)
 WAZ ≤ −3 1.35(1.16–1.57) 1.29(1.08–1.53)
WHZ/BMIZ Score
 WHZ/BMIZ > −1 Reference 0.70
 −2< WHZ/BMIZ ≤ −1 0.84(0.72–0.99)
 −3 < WHZ/BMIZ ≤ −2 1.04(0.87–1.23)
 WHZ/BMIZ ≤ −3 1.01(0.84–1.21)
HAZ Score
 HAZ > −1 Reference 0.044 Reference 0.80
 −2< HAZ ≤ −1 0.93(0.80–1.09) 1.05(0.90–1.24)
 −3 < HAZ ≤ −2 0.97(0.83–1.13) 1.05(0.89–1.23)
 HAZ −3 1.21(1.05–1.40) 1.24(1.06–1.45)
WHO stage
 I Reference <0.0001 Reference 0.06
 II 0.68(0.59– 0.77) 0.83(0.72– 0.95)
 III 0.86(0.76–0.96) 1.05(0.92–1.20)
 IV 1.08(0.88–1.33) 1.20(0.96–1.51)
CD410
 <100 0.70(0.60–0.80) <0.0001 0.82(0.70–0.99) 0.11
 100 – <200 0.51(0.39–0.66) 0.53(0.40–0.71)
 200– <350 0.61(0.52–0.73) 0.70(0.58–0.84)
 350+ Reference Reference
Cotrimoxazole10
 No Reference <0.0001 Reference 0.002
 Yes 1.67(1.29–2.17) 1.39(1.06–1.81)
1Low MUAC is defined as <11.5cm for children <5 years, below 12.9 for children 5–9 years, and <16.0cm for children aged 10+ 
years.
10Only results from time-varying model are shown, but both baseline and time-varying analyses were done.
10Only results from time-varying model are shown, but both baseline and time-varying analyses were done.
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Characteristic Univariate RR 95% CI P for trend Multivariate RR 95% CI P for trend
Anemic, g/dL10
 No Reference 0.1 Reference 0.57
 Yes 0.87(0.76–0.98) 0.99(0.86–1.15)
TB history
 No Reference 0.37
 Yes 0.94 (0.82–1.09)
Diarrhea
 No Reference 0.009 Reference 0.020
 Yes 1.34(1.13–1.55) 1.20(1.03–1.41)
Elevated ALT10
 No Reference 0.95
 Yes 0.98(0.83–1.15)
Opportunistic Infections
 No Reference 0.020 Reference 0.27
 Yes 1.03(0.99–1.17) 1.08(0.97–1.25)
On ARVs
 No Reference <0.0001 Reference 0.002
 Yes 1.56(1.35–1.82) 1.37(1.17–1.61)
ARV Regimen (nucleoside/nucleotide reverse 
transcriptase inhibitor used)
 Contains stavudine 0.88(0.72–1.06) 0.14 1.04(0.87–1.24) 0.66
 No stavudine Reference Reference
ARV Regimen (Non-nucleoside reverse transcriptase 
inhibitor)
 Contains efavirenz 4.18(0.98–18.23) 0.06 3.78(0.86–16.61) 0.31
 No efavirenz Reference Reference
10Only results from time-varying model are shown, but both baseline and time-varying analyses were done.
10Only results from time-varying model are shown, but both baseline and time-varying analyses were done.
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Table 3
Baseline Socio-economic Characteristics in relation to LTFU: 180 events, 495 child-years of follow up




 ≤7 1.22(0.82–1.83) 0.49
 >7 Reference
Mother’s Work
 Employed 1.25(0.92–1.69) 0.71
 Not employed Reference
Mother Married
 No 0.77(0.48–1.25) 0.82
 Yes Reference
Father Education
 ≤7 0.77(0.56–1.07) 0.16 0.83(.60–1.15) 0.10
 >7 Reference Reference
Number of Adults who eat in home everyday
 0–2 Reference 0.53
 >2 0.94(0.70–1.26)
Number of Children <5 years old who eat in home everyday
 0–1 Reference 0.54
 ≥2 0.97(0.55–1.7)
Daily Food Expenditure
 ≤500 Tsh or 0.32 USD 1.30(0.95–1.87) 0.19 1.17(0.81–1.69) 0.97
 >500 Tsh or 0.32 USD Reference Reference
Total Tsh spent on food per person per day
 ≤500 or 0.32 USD 0.88(0.65–1.19) 0.59
 >500 or 0.32 USD Reference
Number of times household eats protein a week
 ≤3 1.41(1.04–1.90) 0.21 1.39(1.05–1.90) 0.05
 >3 Reference Reference
Household Belongings
 Very low (≤2) 1.55(0.87–2.77) 0.72
 Low (3) 1.42(0.76–2.67)
 High (4) 1.39(0.73–2.67)
 Very high (≥5) Reference
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 November 01.
